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Earl S. Ford, MD, MPH, Guixiang Zhao, MD, PHD, Chaoyang Li, MD, PHD
Atlanta, Georgia
Objectives Our objective was to estimate the magnitude of the relative risk (RR) for cardiovascular disease associated with im-
paired fasting glucose (IFG) and impaired glucose tolerance (IGT) from published prospective observational studies.
Background Hyperglycemia is a known risk factor for cardiovascular disease. However, the magnitude of the RR for cardio-
vascular disease associated with IFG and IGT is unclear.
Methods We searched PubMed from 1997 through 2008 for relevant publications and performed a meta-analysis.
Results In 18 publications with information about IFG (110 to 125 mg/dl) (IFG 110), estimates of RR ranged from 0.65
to 2.50. The fixed-effects summary estimate of RR was 1.20 (95% confidence interval [CI]: 1.12 to 1.28). In 8
publications with information about IFG (100 to 125 mg/dl) (IFG 100), estimates of RR ranged from 0.87 to
1.40. The fixed-effects summary estimate of RR was 1.18 (95% CI: 1.09 to 1.28). In 8 publications with informa-
tion about IGT, estimates of RR ranged from 0.83 to 1.34. The fixed-effects summary estimate of RR was 1.20
(95% CI: 1.07 to 1.34). Five studies combined IFG and IGT, yielding a fixed-effects summary estimate of RR of
1.10 (95% CI: 0.99 to 1.23). No significant difference between the summary estimates for men and women
were detected (IFG 110: men: 1.17 [95% CI: 1.05 to 1.31], women: 1.30 [95% CI: 1.10 to 1.54]; IFG 100: men:
1.23 [95% CI: 1.06 to 1.42], women: 1.16 [95% CI: 0.99 to 1.36]).
Conclusions Impaired fasting glucose and IGT are associated with modest increases in the risk for cardiovascular
disease. (J Am Coll Cardiol 2010;55:1310–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.060p
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wyperglycemia is a well-established risk factor for cardio-
ascular disease (1–3). Although the shape of the relation-
hip between 2-h post-load concentrations of glucose is
inearly related to the risk of cardiovascular disease, the
hape of the relationship between fasting concentrations of
lucose and the risk of cardiovascular disease might be
onlinear (2,4). Several meta-analyses have shown that
iabetes imparts a 2- to 3-fold increase in the risk of
eveloping coronary heart disease (5–8). Furthermore, in 2
f these meta-analyses the summary estimate of relative risk
RR) in women significantly exceeded that in men (5,8).
owever, it remains unknown whether the risk between
re-diabetes, generally defined as impaired fasting glucose
IFG) and/or impaired glucose tolerance (IGT), and car-
iovascular disease differs according to sex.
rom the Division of Adult and Community Health, National Center for Chronic
isease Prevention and Health Promotion, Centers for Disease Control and
revention, Atlanta, Georgia. The findings and conclusions in this article are those of
he authors and do not represent the official position of the Centers for Disease
ontrol and Prevention.d
Manuscript received April 10, 2009; revised manuscript received October 15, 2009,
ccepted October 26, 2009.Although a continuum of risk extends into and below the
re-diabetic glucose range, the risk associated with IFG and
GT is not well-established. In 1997, the concept of IFG
as introduced, and IFG was defined as a plasma glucose
oncentration of 110 to 126 mg/dl (9). In 2003, IFG was
edefined as a plasma glucose concentration of 100 to 126
g/dl (10). Several revisions of the glucose criteria for
efining various categories of dysglycemia by the World
ealth Organization (WHO) and American Diabetes As-
ociation (ADA) necessitate re-examining the risk between
re-diabetes and cardiovascular disease with the most recent
efinitions of IFG and IGT (9–12). Understanding such
isk estimates is important, given the increases in the
revalence of IFG and IGT that have occurred in many
opulations characterized by increases in the prevalence of
besity, including the U.S. (13). Therefore, the objectives of
his study included: 1) performing a quantitative review of
rospective studies that reported on the risks of developing
ardiovascular disease among study participants with IFG,
GT, or both to estimate the magnitude of the RR for
re-diabetes and cardiovascular disease; and 2) estimating
hether the RR between pre-diabetes and cardiovascular
isease differed between men and women.
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March 30, 2010:1310–7 Pre-Diabetes and Cardiovascular Diseaseethods
ith PubMed, we searched with the terms “ ‘impaired
asting glucose’ OR IFG OR ‘impaired glucose tolerance’
R IGT OR pre-diabetes OR hyperglycemia” as well as
heart OR cardiovascular OR stroke OR cerebrovascular” and
incidence OR incident OR follow-up OR prospective OR
ongitudinal OR mortality OR death” from 1997 through the
nd of September 2008. We included prospective observational
tudies published in English that reported estimated RRs and
onfidence intervals (CIs) for coronary heart disease or cardio-
ascular disease and excluded studies that were limited to
atients with pre-existing conditions or to patients undergoing
edical procedures. Furthermore, classification of IFG or IGT
ad to be based on 1997 ADA criteria, 2003 ADA criteria, or
HO 1999 criteria (9,10,12). Our search yielded 1,070
itations. After reviewing the abstracts of these publications,
e retrieved and reviewed copies of 52. Thirty-two publica-
ions did not have relevant information (lack of outcome of
nterest, no IFG or IGT, duplicate analyses, no estimate of RR
r CIs). The remaining 20 publications were augmented with
publications that were identified through reviewing bibliog-
aphies and 5 publications that were identified after reviewing
ublications on the metabolic syndrome and cardiovascular
isease. Abstracted information included author, year of pub-
Overall  (I-squared = 28.7%, p = 0.104)
Levitzky 2008: Men
Nakanishi 2004
Wild 2005
Nakagami 2004
DECODE 2001: Men
Lu 2003
McNeill 2005: Men
Henry 2002
DECODE 2001: Women
Palmieri 2006
Wang 2007: Men
Levitzky 2008: Women
Nilsson 2007
McNeill 2005: Women
Wannamethee 2008
Hunt 2004
Saydah 2001
Barr 2007
Wang 2007
Study
ID
Chien 2008
Barzilay 1999
Wang 2007: Women
1.25 .5
Figure 1 Measures of Association Between Impaired Fasting G
Moving from left to right, each row of information shows the first author and year of p
diamond) and confidence interval (CI) (the square box portrays graphically the weight e
each data point contributed to the analysis. The overall summary estimate of RR is sh
ciated with a small increase in risk for cardiovascular disease. DECODE  Diabetes Eication, study name, study loca-
ion, numbers of male and female
articipants, mean age or range,
ollow-up time, cardiovascular dis-
ase end point, number of events,
FG or IGT criteria, estimate of
R and CI, and adjustment vari-
bles. Information was abstracted
y 2 independent reviewers.
We calculated summary esti-
ates of RR for IFG 110 (6.1
o 7.0 mmol/l or 110 to 125
g/dl), IFG 100 (5.6 to 7.0
mol/l or 100 to 125 mg/dl),
GT, and combined IFG 110 and
GT (IFG 110, IGT, or both).
uthors defined IGT inconsis-
ently, although all referred to the WHO or ADA criteria.
ome used only the 2-h glucose concentration (140 to200
g/dl) regardless of fasting concentrations. Others applied
he 2-h glucose concentration criteria only to participants
ith nondiabetic fasting concentrations. All studies that
e included in analyses of IGT used a 75-g oral glucose
olerance test (OGTT). Standard errors (SE) for the esti-
ates of RR were estimated from the CIs. For each study,
1.20 (1.12, 1.28)
1.00 (0.70, 1.50)
1.31 (0.51, 3.34)
1.06 (0.72, 1.57)
1.05 (0.67, 1.65)
1.03 (0.85, 1.25)
0.75 (0.41, 1.36)
1.13 (0.91, 1.39)
1.44 (1.09, 1.90)
1.53 (0.81, 2.90)
1.04 (0.78, 1.39)
1.39 (0.97, 2.00)
2.10 (1.20, 3.60)
1.39 (1.07, 1.81)
0.99 (0.69, 1.42)
1.18 (1.03, 1.35)
1.62 (0.50, 5.25)
0.65 (0.31, 1.34)
2.50 (1.20, 5.10)
1.25 (0.82, 1.92)
Relative
risk (95% CI)
1.87 (1.28, 2.75)
1.28 (1.02, 1.61)
1.32 (0.85, 2.04)
100.00
3.02
0.50
2.89
2.16
11.80
1.22
9.78
5.68
1.08
5.26
3.35
1.45
6.35
3.37
23.98
0.32
0.82
0.84
2.42
%
Weight
3.00
8.42
2.29
2 2.5 5.5
e (110 to 125 mg/dl) and Cardiovascular Outcomes
tion, a graphical portrayal of the estimate of relative risk (RR) (represented by the
stimate contributed to the analysis), the estimate of RR and CI, and the weight that
n the last row of the graph. Impaired fasting glucose of 110 to 125 mg/dl is asso-
iology: Collaborative analysis of Diagnostic criteria in Europe.
Abbreviations
and Acronyms
ADA  American Diabetes
Association
CI  confidence interval
IFG  impaired fasting
glucose
IGT  impaired glucose
tolerance
OGTT  oral glucose
tolerance test
RR  relative risk
SE  standard error
WHO  World Health
Organization1.5
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Pre-Diabetes and Cardiovascular Disease March 30, 2010:1310–7weight was calculated as the inverse of the variance
1/SE2). Heterogeneity among studies was assessed with the
statistic (14). If no heterogeneity was present (p Q
tatistic 0.10), fixed-effects estimates of RR were calcu-
ated according to the inverse variance method (15). If
eterogeneity was present (p Q statistic 0.10), random-
ffects estimates of RR were calculated with the approach by
erSimonian and Laird (14). We also considered, in
ddition to the statistical approach to testing for the
resence of heterogeneity, how various study characteristics
uch as follow-up time might influence the analyses. The
nfluence of single studies on the summary estimates was
xamined graphically by checking how the elimination of
ach study affected the resulting summary estimate of RR
16). The Egger’s test was used to look for possible
ublication bias (17). Analyses were conducted in Stata
ersion 10 (StataCorp, College Station, Texas).
esults
elected characteristics of studies that were included in our
nalyses are shown in the Online Supplement (18–42).
ighteen publications that included 175,152 participants
rovided estimates of RR associated with IFG 110
18,19,21,22,25,26,28–30,32,36–43): the DECODE study
Diabetes Epidemiology: Collaborative analysis of Diagnos-
ic criteria in Europe) was based on data from 10 European
ohorts (19), and the DECODA (Diabetes Epidemiology:
ollaborative analysis Of Diagnostic criteria in Asia) study
Overall  (I-squared = 0.4%, p = 0.437)
Study
Wang 2007: Women
Tai 2004
Levitzky 2008: Women
Wang 2007
Liu 2007
Wang 2007: Men
Levitzky 2008: Men
Pankow 2007
ID
McNeill 2006: Women
McNeill 2006: Men
Rijkelijkhuizen 2007
1.5
Figure 2 Measures of Association Between Impaired Fasting G
Moving from left to right, each row of information shows the first author and year
by the diamond) and confidence interval (CI) ((the square box portrays graphically
the weight that each data point contributed to the analysis. The overall summary e
to 125 mg/dl is associated with a small increase in risk for cardiovascular diseasncluded data from 5 cohorts (25). Sixteen publications
ncluded men and women, and 2 publications included only
en. Fourteen publications emanated from Australia, Eu-
ope, and the U.S., and 4 publications included Asian
articipants. Estimates of RR of coronary heart disease or
ardiovascular disease ranged from 0.65 (21) to 2.50 (39)
Fig. 1). No significant heterogeneity existed among the
tudies (p  0.104, I2  28.7%), and the fixed-effects
ummary estimate of RR was 1.20 (95% CI: 1.12 to 1.28).
hen we used 2003 DECODE data (23) instead of 2001
ECODE data (19), the fixed-effects summary estimate of
R was 1.19 (95% CI: 1.12 to 1.27).
When we separated the 18 publications into 2 groups—1
hat adjusted for age, smoking status, blood pressure, and
ipids (18,19,21,25,26,30,40,43); and 1 that did not adjust
or all these variables (22,28,29,32,36 –39,41,42)—the
xed-effects summary estimate of RR for the 8 studies that
id adjust for the risk factors was 1.12 (95% CI: 1.00 to
.25), and the fixed-effects summary estimate of RR for the
studies that did not adjust for the all the risk factors was
.24 (95% CI: 1.15 to 1.35). Although the estimate of RR
or the group of studies that incorporated the adjustment
as lower than the estimate for the other group, the 2
stimates did not differ significantly (p  0.129).
The 8 publications with information about the estimated
R associated with IFG 100 included 52,994 participants
27,33–35,37,38,40,44). All publications included men and
omen, and 3 were from Asia, 3 from the U.S., and 2 from
1.18 (1.09, 1.28)
Relative
1.29 (0.90, 1.84)
1.25 (0.85, 1.83)
1.40 (0.90, 2.10)
1.08 (0.73, 1.60)
1.29 (1.10, 1.51)
1.28 (0.88, 1.86)
1.10 (0.80, 1.40)
0.87 (0.67, 1.12)
risk (95% CI)
1.08 (0.89, 1.31)
1.28 (1.05, 1.57)
1.37 (0.87, 2.16)
100.00
%
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lication, a graphical portrayal of the estimate of relative risk (RR) (represented
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March 30, 2010:1310–7 Pre-Diabetes and Cardiovascular Diseaseurope. Estimates of RR ranged from 0.87 (44) to 1.40 (40) (Fig.
). There was no statistical evidence for heterogeneity among
he studies (p  0.437, I2  0.4%), and the fixed-effects
ummary estimate of RR was 1.18 (95% CI: 1.09 to 1.28). All
f the studies of IFG 100 adjusted for age, smoking status,
lood pressure, and lipids.
The 8 publications with information about the estimated
R associated with IGT included 53,512 participants
19,21,25,30,38,39,42,44). All publications included men
nd women, and 3 were from Asia, 2 from Europe, 2 from
he U.S., and 1 from Australia. Estimates of RR ranged
rom 0.83 (44) to 1.34 (19) (Fig. 3). There was no statistical
vidence for heterogeneity among the studies (p  0.512,
2  0.0%), and the fixed-effects summary estimate of RR
as 1.20 (95% CI: 1.07 to 1.34). One additional study
ontained information about the RR for ischemic heart
isease among participants with IGT stratified by level of
asting glucose (27). After estimating a single overall RR for
GT and combining this information with that from the
ther studies, the fixed-effects summary estimate of RR was
.24 (95% CI: 1.11 to 1.38). Six of the 8 studies adjusted for
ge, smoking status, blood pressure, and lipids (fixed-effects
ummary estimate of RR: 1.20, 95% CI: 1.06 to 1.35). For
of the 8 studies that also included estimates for IFG 110,
he fixed-effects summary estimate of RR for IGT was 1.25
95% CI: 1.11 to 1.41), and the fixed-effects summary
stimate of RR for IFG 110 was 1.17 (95% CI: 1.02 to
.34). Four of the 8 studies defined IGT on the basis of
asting and 2-h glucose criteria (21,30,39,44), and the
Overall  (I-squared = 0.0%, p = 0.512)
Chien 2008*
ID
DECODE 2001: Women*
Wang 2007*
Saydah 2001
Wild 2005
Pankow 2007
Barr 2007
Nakagami 2004*
DECODE 2001: Men*
Study
1.25 .5
Figure 3 Measures of Association Between Impaired Glucose T
Moving from left to right, each row of information shows the first author and year
by the diamond) and confidence interval (CI) (the square box portrays graphically t
the weight that each data point contributed to the analysis. The overall summary e
associated with a small increase in risk for cardiovascular disease. *Studies that
studies used 2-h and fasting concentrations of glucose to define impaired glucosexed-effects summary estimate of RR was 0.97 (95% CI: 0.79
o 1.21). For the other 4 studies that defined IGT only on the
asis of 2-h glucose criteria, the fixed-effects summary estimate
f RR was 1.30 (95% CI: 1.13 to 1.48) (19,25,38,42).
Five studies created categories of dysglycemia that com-
ined IFG and IGT (20,24,25,31,38). The studies included
9,893 participants. All publications included men and
omen. Follow-up times ranged from 5 to 21.5 years. Two
ublications included participants of Asian heritage or from
sia, 2 studies were conducted in Europe, and 1 study was
onducted in the U.S. There was no statistical evidence for
eterogeneity (p  0.731, I2  0%), and the fixed-effects
ummary estimate of RR was 1.10 (95% CI: 0.99 to 1.23)
Fig. 4).
We also examined the summary estimates of RR for a set
f studies that provided estimated RRs for both IFG 100
nd IFG 110 (Fig. 5) (33,34,37,38,40). The fixed-effects
ummary estimates of RR were 1.37 (95% CI: 1.21 to 1.55)
or IFG 110 and 1.19 (95% CI: 1.08 to 1.32) for IFG 100.
ex differences. Five publications with information about
FG 110 provided separate estimates of RR for men and
omen (Fig. 6A) (19,29,33,37,40). The fixed-effects sum-
ary estimate of RR was 1.17 (95% CI: 1.05 to 1.31) for
en and 1.30 (95% CI: 1.10 to 1.54) for women. However,
he 2 estimates did not differ significantly (p  0.251).
Three publications with information about IFG 100
rovided separate estimates of RR for men and women (Fig.
B) (33,37,40). The fixed-effects summary estimate of RR
as 1.23 (95% CI: 1.06 to 1.42) for men and 1.16 (95% CI:
1.20 (1.07, 1.34)
1.20 (0.80, 1.79)
risk (95% CI)
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lication, a graphical portrayal of the estimate of relative risk (RR) (represented
ght each estimate contributed to the analysis), the estimate of RR and CI, and
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iffer significantly (p  0.614).
iscussion
ur review indicates that the estimated RR for cardiovas-
ular disease associated with IGT might range from 0.97 to
.30 and that associated with IFG ranges from approxi-
ately 1.12 to 1.37, depending on the set of studies
ncluded in a particular analysis. Furthermore, the risk
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Figure 5 Estimated RRs for Cardiovascular Outcomes for Studi
Fasting Glucose Defined as 110 to 125 mg/dl (IFG 1
The results show that the magnitude of the estimated relative risk (RR) associated
[CI]: 1.21 to 1.55) is larger than that associated with IFG 100 (RR: 1.19, 95% CI:
Overall  (I-squared = 0.0%, p = 0.731)
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ID
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Figure 4 Measures of Association Between Combined Impaired
and Impaired Glucose Tolerance and Cardiovascular O
Moving from left to right, each row of information shows the first author and year
by the diamond) and confidence interval (CI) (the square box portrays graphically t
the weight that each data point contributed to the analysis. The overall summary e
impaired fasting glucose and impaired glucose tolerance is associated with a smassociated with IFG 110 was larger than that for IFG 100.
t present, the available data are insufficient to confirm the
resence of a sex difference in the risk between pre-diabetes
nd cardiovascular disease.
Some reviews have suggested that IGT increased the risk
or macrovascular disease by approximately 2-fold (45).
uch conclusions reflected the results of some studies that
id find that IGT approximately doubled the risk for
ardiovascular disease (46–50). Subsequent studies that
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March 30, 2010:1310–7 Pre-Diabetes and Cardiovascular Diseaseere based on the 1980 or 1985 WHO criteria in which
GT was defined as a fasting plasma concentration of
lucose of 140 mg/dl and a 2-h concentration of glucose
f 140 to 200 mg/dl also reported an approximate
oubling of risk for cardiovascular disease among partici-
ants with IGT (51,52). However, other studies using the
980 or 1985 WHO classification found estimates of RR of
pproximately 1.15 to 1.22 (18,21,53). By reclassifying
ormal glucose tolerance and IGT, it is likely that the
bsolute risk for developing cardiovascular disease was
owered for people meeting the WHO 1999 criteria for
ormal glucose tolerance and IGT. However, the net effect
f this reclassification on the RR associated with IGT
emained unclear.
Our analysis of studies examining the impact of IGT on
ardiovascular disease included several studies that only used
he 2-h glucose criteria of 140 to 200 mg/dl. Thus,
hese studies also included participants with diabetes de-
ned on the basis of fasting glucose criteria. The risk for
Figure 6 Sex-Specific Estimates of RR Between IFG 110 and IF
(A) Impaired fasting glucose (IFG) 110 defined as IFG 110 to 125 mg/dl. (B) IFG 1
not differ significantly between men and women for either IFG 110 or IFG 100. DEeveloping cardiovascular disease among these participants tas likely higher than that for participants whose fasting
lucose concentration was 126 mg/dl. In fact, the esti-
ated summary RR was 1.30 for the 3 publications exam-
ning the 2-h glucose abnormality compared with 0.97 for
he 4 studies using WHO criteria for IGT, although the 2
stimates were not significantly different.
Some early studies suggested that the estimated RR of
ortality from coronary heart disease was greater among
omen with borderline diabetes than men (48). The limited
ex-specific data concerning the risks for cardiovascular
isease associated with pre-diabetes included in the present
tudy did not support a significant sex difference in the
stimates of RR. Although more data were available for
FG 110 than for IFG 100, the number of such studies was
till limited. Regarding IGT, there are currently insufficient
ata to arrive at a conclusion concerning potential sex
ifferences. Of note is the finding from the DECODE
tudy in 2001 that the RRs for cardiovascular disease among
articipants with 2-h glucose abnormalities corresponding
0 and Cardiovascular Outcomes
ned as IFG 100 to 125 mg/dl. The summary estimates of relative risk (RR) do
 Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe.G 10
00 defi
CODEo IGT were very similar for men and women (19). More
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Pre-Diabetes and Cardiovascular Disease March 30, 2010:1310–7tudies are needed to better delineate the sex-specific risks
ttributable to IFG and IGT.
Because most prospective studies employ a single deter-
ination of glycemic status at baseline, the question arises
s to whether the risk for developing cardiovascular disease
s confined to people with pre-diabetes who develop diabe-
es or whether the risk is still increased among people with
re-diabetes even if they never develop diabetes. At least 2
ttempts have been made to address this issue and have
ailed to produce definitive insights into this issue (34,54).
Current recommendations to screen for pre-diabetes
re inconsistent. The U.S. Preventive Services Task
orce does not support screening for pre-diabetes,
hereas the ADA supports screening among people at
ncreased risk on the basis of age and body mass index.
ne of the key issues to be addressed when recommen-
ations concerning screening are being debated is the
eriousness of potential consequences in terms of mor-
idity and mortality if a condition is not detected. The
ather modest summary estimates of RR for cardiovascu-
ar disease that we calculated suggest that any future
onsideration concerning screening for pre-diabetes is
ikely to be governed principally by the risk of developing
iabetes rather than cardiovascular disease. Nevertheless,
n economic analysis that incorporates the prevention of
ardiovascular disease might provide additional useful
nformation to steer future discussions concerning the
eed to screen for pre-diabetes in the general population
r in specific population groups at high risk. Further-
ore, our results, which show rather similar estimates of
R for cardiovascular disease for IFG and IGT, might
lso contribute to the debate as to whether an OGTT is
eally needed to identify people at increased risk for
ardiovascular disease or whether a fasting glucose mea-
urement suffices. If the RRs for cardiovascular disease
or the 2 forms of hyperglycemia are similar, then the
hief advantage of conducting an OGTT is reduced to
dentifying greater numbers of people with pre-diabetes.
f course, this comes at the expense of greater cost and
atient inconvenience.
The degree of adjustment for potential confounders
as limited in many studies, especially in studies that
rovided risk estimates for the individual components of
he metabolic syndrome. Furthermore, some potential
onfounders such as physical activity were rarely incor-
orated into the analyses. Thus, it is possible that the true
R for cardiovascular disease attributable to pre-diabetes
ight be even less than that estimated in this study.
nother point worth considering is that the number of
vents among participants with pre-diabetes was rather
mall in a number of studies, leading to considerable
ncertainty about the magnitude of the RR as reflected by
he wide CIs. Although we did not detect publication
ias, our ability to do so was limited because of the small
umber of data points in most analyses.
1onclusions
he exact magnitude of the risk for cardiovascular disease
ssociated with IFG or IGT remains opaque at present.
epending on the set of studies examined, our analyses
ould be interpreted as implying no increase in risk for
ardiovascular disease or at most a very modest increase in
isk. Furthermore, there is no compelling evidence to
uggest that the estimated RR for IGT is greater than that
or IFG. Given the sizeable and growing percentage of
dults who have pre-diabetes in some countries like the U.S.
13), a small increase in risk, assuming a causal relationship
etween pre-diabetes and cardiovascular disease, might still
ranslate into substantial numbers of adults developing or
ying from cardiovascular disease. The limited number of
tudies examining the risk for cardiovascular disease associ-
ted with IFG 100 and IGT according to WHO criteria
hould spur sustained efforts to clarify the relationship
etween pre-diabetes and cardiovascular disease.
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isease Control and Prevention, 4770 Buford Highway, MS K66,
tlanta, Georgia 30341. E-mail: eford@cdc.gov.
EFERENCES
1. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship
between glucose and incident cardiovascular events. A metaregression
analysis of published data from 20 studies of 95,783 individuals
followed for 12.4 years. Diabetes Care 1999;22:233–40.
2. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a
risk factor for cardiovascular disease? A meta-analysis of prospective
studies. Arch Intern Med 2004;164:2147–55.
3. Danaei G, Lawes CM, Vander HS, Murray CJ, Ezzati M. Global and
regional mortality from ischaemic heart disease and stroke attributable
to higher-than-optimum blood glucose concentration: comparative
risk assessment. Lancet 2006;368:1651–9.
4. The DECODE Study Group, the European Diabetes Epidemiology
Group. Glucose tolerance and cardiovascular mortality: comparison of
fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:
397–405.
5. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on
coronary artery disease in women and men: a meta-analysis of
prospective studies. Diabetes Care 2000;23:962–8.
6. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference
in coronary heart disease mortality among patients with type 2 diabetes
mellitus: a meta-analysis. Arch Intern Med 2002;162:1737–45.
7. Huxley R, Woodward M, Barzi F, Wong JW, Pan WH, Patel A.
Does sex matter in the associations between classic risk factors and
fatal coronary heart disease in populations from the Asia-Pacific
region? J Womens Health (Larchmt) 2005;14:820–8.
8. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart
disease associated with diabetes in men and women: meta-analysis of
37 prospective cohort studies. BMJ 2006;332:73–8.
9. The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus. Report of the Expert Committee on the Diagnosis and Classi-
fication of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.
0. The Expert Committee on the Diagnosis and Classification of
Diabetes Mellitus. Report of the Expert Committee on the Diagnosis
and Classification of Diabetes Mellitus. Diabetes Care 2003;26 Suppl
1:S5–20.
1. World Health Organization. Diabetes Mellitus. Report of a WHO
Study Group. Technical Report Series 727. Geneva: World Health
Organization, 1985.2. World Health Organization. Definition, diagnosis and classification of
diabetes mellitus and its complications. Report of a WHO consulta-
11
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
K
h
F
1317JACC Vol. 55, No. 13, 2010 Ford et al.
March 30, 2010:1310–7 Pre-Diabetes and Cardiovascular Diseasetion. Part 1: diagnosis and classification of diabetes mellitus. WHO/
NCD/NCS/99.2. Geneva: World Health Organization, 1999.
3. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and
pre-diabetes in the U.S. population in 1988–1994 and 2005–2006.
Diabetes Care 2009;32:287–94.
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials 1986;7:177–88.
5. Greenland S. Quantitative methods in the review of epidemiologic
literature. Epidemiol Rev 1987;9:1–30.
6. Tobias A. Assessing the influence of a single study in meta-analysis.
Stata Tech Bull 1999;47:15–7.
7. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997;315:629–34.
8. Barzilay JI, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in
older adults with glucose disorders: comparison of American Diabetes
Association criteria for diabetes mellitus with WHO criteria. Lancet
1999;354:622–5.
9. The DECODE Study Group. Glucose tolerance and cardiovascular
mortality: comparison of fasting and 2-hour diagnostic criteria. Arch
Intern Med 2001;161:397–405.
0. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states
of glucose intolerance and risk of death in the U.S. Diabetes Care
2001;24:447–53.
1. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL.
Postchallenge hyperglycemia and mortality in a national sample of
U.S. adults. Diabetes Care 2001;24:1397–402.
2. Henry P, Thomas F, Benetos A, Guize L. Impaired fasting glucose,
blood pressure and cardiovascular disease mortality. Hypertension
2002;40:458–63.
3. The DECODE Study Group. Is the current definition for diabetes
relevant to mortality risk from all causes and cardiovascular and
noncardiovascular diseases? Diabetes Care 2003;26:688–96.
4. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and
coronary heart disease in the metabolic syndrome: prospective data
from the Bruneck study. Diabetes Care 2003;26:1251–7.
5. Nakagami T. Hyperglycaemia and mortality from all causes and from
cardiovascular disease in five populations of Asian origin. Diabetologia
2004;47:385–94.
6. Nakanishi N, Takatorige T, Fukuda H, et al. Components of the
metabolic syndrome as predictors of cardiovascular disease and type 2
diabetes in middle-aged Japanese men. Diabetes Res Clin Pract
2004;64:59–70.
7. Tai ES, Goh SY, Lee JJ, et al. Lowering the criterion for impaired
fasting glucose: impact on disease prevalence and associated risk of
diabetes and ischemic heart disease. Diabetes Care 2004;27:1728–34.
8. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP.
National Cholesterol Education Program versus World Health Orga-
nization metabolic syndrome in relation to all-cause and cardiovascular
mortality in the San Antonio Heart Study. Circulation 2004;110:
1251–7.
9. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic
syndrome and 11-year risk of incident cardiovascular disease in the
atherosclerosis risk in communities study. Diabetes Care 2005;28:385–90.
0. Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously
undiagnosed diabetes and risk of mortality: 15-year follow-up of the
Edinburgh Artery Study cohort. Diabet Med 2005;22:490–6.
1. Thrainsdottir IS, Aspelund T, Hardarson T, et al. Glucose abnormal-
ities and heart failure predict poor prognosis in the population-based
Reykjavik Study. Eur J Cardiovasc Prev Rehabil 2005;12:465–71.
2. Palmieri L, Donfrancesco C, Giampaoli S, et al. Favorable cardiovas-
cular risk profile and 10-year coronary heart disease incidence in
women and men: results from the Progetto CUORE. Eur J Cardiovasc
Prev Rehabil 2006;13:562–70.
3. McNeill AM, Katz R, Girman CJ, et al. Metabolic syndrome and
cardiovascular disease in older people: the cardiovascular health study.
J Am Geriatr Soc 2006;54:1317–24.
4. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD,
Dekker JM. High risk of cardiovascular mortality in individuals with
impaired fasting glucose is explained by conversion to diabetes: the
Hoorn study. Diabetes Care 2007;30:332–6.
5. Liu J, Grundy SM, Wang W, et al. Ten-year risk of cardiovascular
incidence related to diabetes, prediabetes, and the metabolic syndrome.
Am Heart J 2007;153:552–8. a6. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and
incidence of cardiovascular disease in non-diabetic subjects—a
population-based study comparing three different definitions. Diabet
Med 2007;24:464–72.
7. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto
J. The metabolic syndrome predicts cardiovascular mortality: a 13-year
follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:
857–64.
8. Wang JJ, Li HB, Kinnunen L, et al. How well does the metabolic
syndrome defined by five definitions predict incident diabetes and
incident coronary heart disease in a Chinese population? Atheroscle-
rosis 2007;192:161–8.
9. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and
all-cause mortality in individuals with diabetes mellitus, impaired
fasting glucose, and impaired glucose tolerance: the Australian Dia-
betes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:
151–7.
0. Levitzky YS, Pencina MJ, D’Agostino RB, et al. Impact of impaired
fasting glucose on cardiovascular disease: the Framingham Heart
Study. J Am Coll Cardiol 2008;51:264–70.
1. Wannamethee SG. The metabolic syndrome and cardiovascular risk in
the British Regional Heart Study. Int J Obes (Lond) 2008;32 Suppl
2:S25–9.
2. Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Fasting and
postchallenge hyperglycemia and risk of cardiovascular disease in
Chinese: the Chin-Shan Community Cardiovascular Cohort study.
Am Heart J 2008;156:996–1002.
3. Lu W, Resnick HE, Jain AK, et al. Effects of isolated post-challenge
hyperglycemia on mortality in American Indians: the Strong Heart
Study. Ann Epidemiol 2003;13:182–8.
4. Pankow JS, Kwan DK, Duncan BB, et al. Cardiometabolic risk in
impaired fasting glucose and impaired glucose tolerance: the Athero-
sclerosis Risk in Communities Study. Diabetes Care 2007;30:325–31.
5. Laakso M. Hyperglycemia and cardiovascular disease in type 2
diabetes. Diabetes 1999;48:937–42.
6. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-
disease risk and impaired glucose tolerance. The Whitehall study.
Lancet 1980;1:1373–6.
7. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an
epidemiologic view. Diabetes Metab Rev 1987;3:463–524.
8. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year
mortality rates in newly diagnosed diabetics, borderline diabetics and
normoglycaemic controls and risk indices for coronary heart disease in
borderline diabetics. Diabetologia 1982;22:79–84.
9. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from
coronary heart disease and stroke in relation to degree of glycaemia: the
Whitehall study. Br Med J (Clin Res Ed) 1983;287:867–70.
0. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease
mortality in relation with diabetes, blood glucose and plasma insulin
levels. The Paris Prospective Study, ten years later. Horm Metab Res
Suppl 1985;15:41–6.
1. Fujishima M, Kiyohara Y, Kato I, et al. Diabetes and cardiovascular
disease in a prospective population survey in Japan: The Hisayama
Study. Diabetes 1996;45 Suppl 3:S14–6.
2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A.
Impaired glucose tolerance is a risk factor for cardiovascular disease,
but not impaired fasting glucose. The Funagata Diabetes Study.
Diabetes Care 1999;22:920–4.
3. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated
with all-cause and cardiovascular mortality in the Hoorn population:
the Hoorn Study. Diabetologia 1999;42:926–31.
4. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of
impaired glucose tolerance for cardiovascular risk are not explained by
the development of overt diabetes during follow-up. Diabetes Care
2003;26:2910–4.
ey Words: cardiovascular diseases y coronary heart disease y
yperglycemia y meta-analysis y prediabetic state y review.
APPENDIX
or the selected characteristics of studies that were included in our
nalyses, please see the online version of this article.
